NAD+ IV Therapy Marketing and the FDA Position: What Actually Has Approval, What Does Not, and How to Word It
Most NAD+ IV therapy marketing trouble is upstream of the FTC longevity-claim issue. It is the quiet implication that NAD+ has some kind of FDA status it does not have. Here is the actual FDA position and how to word a NAD+ program page around it.
Most NAD+ IV therapy marketing trouble is not the longevity claim. The longevity-claim issue is downstream. The upstream issue, and the one that survives every rewrite of the anti-aging language, is the quiet implication that NAD+ has some kind of FDA approval status that it does not have. Once you get the FDA-status sentence right, the rest of the page is easier to write.
This is a focused note on the FDA position around NAD+ infusion products and the marketing language that survives a regulator review. For the broader longevity, anti-aging, and cognitive- enhancement claim categories, see our companion post on NAD+ marketing compliance.
What actually has FDA status, in plain language
- Nicotinamide. A form of vitamin B3, available as an FDA-approved prescription product for specific medical uses such as pellagra. This is not the same product as a compounded NAD+ IV bag.
- Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).Sold as dietary supplements. NMN’s regulatory posture has shifted; FDA has taken the position that NMN does not qualify as a dietary ingredient because it was first studied as a drug. NR continues to be marketed as a supplement under DSHEA. Either way, this is the supplement framework, with the required DSHEA disclaimer.
- NAD+ for IV infusion. Typically prepared as a compounded sterile preparation by a licensed compounding pharmacy under section 503A or 503B. There is no FDA-approved drug product called NAD+ for IV infusion. The compounded product is not the same as an approved drug.
- NAD+ subcutaneous injections. Same regulatory posture as IV - compounded preparation, no FDA approval as a finished drug product for the marketed indications.
Five FDA-position pitfalls in NAD+ marketing
Pitfall 1: Borrowing nicotinamide’s status for NAD+
“NAD+ is an FDA-approved compound used in medical treatment.”
“NAD+ as administered in our IV program is a compounded sterile preparation provided by a licensed compounding pharmacy. There is no FDA-approved drug product called NAD+ for IV infusion in the wellness context. Nicotinamide, a related vitamin B3 compound, has separate FDA-approved uses.”
Why: The bad version blurs nicotinamide approval status onto compounded NAD+. The FDA does not treat these as the same product, and warning letters in adjacent compounded-product categories show this is the kind of equivalence the agency reads as misleading.
Pitfall 2: Calling compounded NAD+ a drug therapy
“NAD+ therapy is a cellular medicine that reverses age-related decline.”
“NAD+ IV is a wellness service that delivers a compounded preparation of nicotinamide adenine dinucleotide; it is not an FDA-approved treatment for aging or any disease.”
Why: Therapy and medicine for a non-approved indication moves the copy into disease-claim territory under FDA rules. Wellness service or program is the framing that holds up.
Pitfall 3: Importing supplement-tier evidence for the IV product
“A landmark NAD+ study showed it boosts cellular energy in humans.”
“Research on NAD+ precursor supplementation in humans is ongoing; findings to date typically involve oral nicotinamide riboside or nicotinamide mononucleotide in healthy adults, not compounded IV NAD+. We do not extrapolate those results to IV outcomes.”
Why: Most of the citeable human research on the NAD+ axis is in oral precursors, not in compounded IV. Borrowing oral-supplement evidence to substantiate an IV product is the Pom Wonderful FTC substantiation pattern.
Pitfall 4: DSHEA disclaimer missing on supplement adjuncts
“Maintain your NAD+ between visits with our daily NR capsules - supports energy, focus, and longevity.”
“Our daily NR supplement is a dietary supplement that supports cellular function. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”
Why: If you sell NR or NMN alongside the IV, that part of the offer is under DSHEA. The disclaimer is mandatory and longevity is the kind of word that pushes a structure-function claim into disease-claim territory.
Pitfall 5: Medical-grade and pharmaceutical-grade euphemisms
“Our pharmaceutical-grade NAD+ delivers what supplements cannot.”
“Our NAD+ IV uses a compounded sterile preparation from a state-licensed compounding pharmacy. Compounded is the accurate term; the product is not a pharmaceutical-grade manufactured drug.”
Why: Pharmaceutical-grade and medical-grade are marketing words, not FDA terms of art. When used to imply parity with an approved drug, they cross into the same equivalence pattern as FDA-approved.
A defensible NAD+ program page sentence-by-sentence
The following is the kind of language we see survive review. Adapt the wording to your clinic; the structure is the part that matters.
- What it is: NAD+ IV is a wellness service in which a compounded preparation of nicotinamide adenine dinucleotide is administered intravenously by licensed clinical staff.
- FDA status: NAD+ for IV infusion in the wellness context is a compounded preparation. It is not an FDA-approved drug product, and is not approved by the FDA for any specific medical indication.
- What patients report: Some patients describe subjective improvements in energy or mental clarity after treatment; these are individual experiences and do not represent clinical evidence of specific outcomes.
- What we do not claim: We do not claim NAD+ treats, prevents, or reverses aging, cognitive decline, neurodegenerative disease, addiction, or any other medical condition.
- Who decides: Eligibility is determined during a clinical consultation; NAD+ is not appropriate for every patient.
Adjacent reading
NAD+ infusion programs frequently sit next to ozone and other IV offerings inside the same clinic. The ozone marketing rules are narrower and sharper - see ozone therapy marketing compliance for the parallel.
Built for this exact problem
Scan your clinic's content before regulators do.
RegenCompliance checks every word of your marketing against live FDA and FTC enforcement data - and rewrites violations automatically. A 30-second scan can save a $50,000–$5M regulatory response.
Related in the platform
Weekly compliance brief
One email a week. New enforcement actions, rule changes, and tactical fixes. No spam, unsubscribe anytime.
Keep reading
Compounded GLP-1 Marketing Compliance in 2026: What Changed When the Shortage List Closed
When the FDA declared the semaglutide and tirzepatide shortages resolved, the legal basis for routine 503A compounding narrowed. Your existing compounded-GLP-1 marketing was probably written for the old posture. Here is the 2026 rewrite.
Read articleKetamine Clinic Marketing Compliance Guide: IV Ketamine for Depression Without Triggering an FDA Letter
Most ketamine clinic marketing problems are not exotic - they are six or seven repeated phrases that the FDA October 2023 communication and 2024 enforcement actions have already singled out. This guide focuses on the IV ketamine for depression use case and rewrites the patterns that get clinics in trouble.
Read articleOzone Therapy Marketing Compliance Rules: The FDA Position on Medical Ozone and the Phrases That Trigger Action
The FDA has stated publicly that ozone is a toxic gas with no known useful medical application. That position is the entire frame for ozone therapy marketing. Most ozone clinic copy is written as if the FDA is silent on the topic - it is not.
Read article